Travere Therapeutics, Inc. TVTX Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Travere Therapeutics, Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Travere Therapeutics, Inc.'s total equity?
- Travere Therapeutics, Inc. (TVTX) reported total equity of $98.73M in Q1 2026.
- How has Travere Therapeutics, Inc.'s total equity changed year-over-year?
- Travere Therapeutics, Inc.'s total equity increased by 200.8% year-over-year, from $32.82M to $98.73M.
- What is the long-term trend for Travere Therapeutics, Inc.'s total equity?
- Over 5 years (2020 to 2025), Travere Therapeutics, Inc.'s total equity has grown at a -11.5% compound annual growth rate (CAGR), from $211.21M to $114.83M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.